Navigation Links
Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
Date:11/10/2008

LAWRENCEVILLE, N.J., Nov. 10 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced results of a recent survey of ophthalmologists regarding issues in the treatment of moderate to severe cases of dry eye. Aton provides the dry eye medication Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, sustained release prescription insert that helps to retain moisture, stabilize the tear film, and lubricate the eye.

Nearly all of the ophthalmologists surveyed (94%) believe more treatment options are needed for moderate to severe dry eye. While 80% feel current therapies are effective for mild dry eye, only 33% feel they are effective for moderate dry eye and 67% feel they are only somewhat effective or not very effective. Only 5% feel current therapies are effective for severe dry eye, while 56% feel they are somewhat effective and 38%, not very or not at all effective.

"Ophthalmologists are still looking for more effective therapies for treating moderate to severe dry eye," commented Dr. Penny Asbell, Professor, Department of Ophthalmology, Mount Sinai School of Medicine; Director, Cornea Services and Refractive Surgery Center, New York; and co-author of the pivotal textbook 'Dry Eye Disease, the Clinician's Guide to Diagnosis and Treatment.' "Nearly all ophthalmologists want more treatment options for these more serious cases." Dr. Asbell is a member of Aton Pharma's Scientific Advisory Board.

"We are proud to be working with Dr. Asbell to contribute to eye care professionals' insights about the state of the art of treatment of dry eye," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "Ophthalmology is one of the important markets Aton serves as a diversified specialty pharmaceutical company providing medically essential therapies to patients around the world."

Treatment Approaches and Options

The survey respondents reported that over the
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Survey: 90% of Participating Surgeons Report Syndicom SpineConnect Improves Practice of Spine Surgery
2. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
3. Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
10. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)...  Lisa Kulik saw fireworks for the first time ... to a groundbreaking retinal implant co-invented by Mark ... the University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative ... June 2, she became the first person west of ...
(Date:8/27/2014)... Mass. (PRWEB) August 27, 2014 “We ... top technology vendors,” said Ven Thangaraj, CEO of Radiant ... solutions that are taking the imaging corelab market to ... sponsors, corelabs and research organizations to efficiently and effectively ... prepare the data to be analyzed and read by ...
(Date:8/27/2014)... Reportbuyer.com has added a new market ... A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds graphene, ... to water treatment, but is graphene the only ... Graphene Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Enzyme for Pulp & Paper Industry Report 2014" ... Enzyme for Pulp & Paper Industry Report 2014 is ... of the global enzyme for pulp & paper industry. ... the industry including definitions, classifications, applications and industry chain ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Novavax, Inc. (Nasdaq:,NVAX) Novavax today announced Chief Executive Officer ... Healthcare Conference at,5:05 am Eastern time (11:05 am CEST) ... Monaco, the company announced today., Dr. Singhvi will ... progress and its unique manufacturing solution. A,link to an ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced ... for Oxyglobin(R) solution [hemoglobin glutamer-200,(bovine)] or HBOC-301, in ... canine anemia, a potentially life-threatening condition.,Under the terms ... 60 mL,single dose and 125 mL single dose ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today reported ... 31, 2008., "We had a productive start ... refocusing our operations to advance four high-value,programs," said ... recent decision to license R3487/MEM 3454 highlights the ...
Cached Biology Technology:Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 7
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the Genetics Society of America,s 27th ... October 3, 2014 in Pacific Grove, California. ... entry of students, post doctorates and scientists from ... science community and to encourage the participation of ...
(Date:8/28/2014)... DURHAM, N.C. -- Scientists have identified the developmental on-off ... microbes that produce more than two-thirds of the world,s ... would be to see whether it is possible to ... efficient. , The study, appearing August 28 in ... a small molecule called cyclic-di-GMP and a larger protein ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... UPTON, NY Hydrogen gas offers one of the ... But traditional methods of producing pure hydrogen face significant ... harmful carbon dioxide into the atmosphere or requiring rare ... scientists at the U.S. Department of Energy,s (DOE) Brookhaven ...
... press release is available in German . ... more,autonomy and far more freedom of discretion. Today, the ... a result of which KIT will be principal of ... future. In,addition, KIT will have the right to make ...
... rats demonstrates that the anti-epilepsy drug phenobarbital stunts neuronal ... first-line drug to treat epilepsy in human newborns. ... May 11, researchers at Georgetown University Medical Center (GUMC) ... pups about a week old changed the way the ...
Cached Biology News:Low-cost nanosheet catalyst discovered to split hydrogen from water 2Low-cost nanosheet catalyst discovered to split hydrogen from water 3Low-cost nanosheet catalyst discovered to split hydrogen from water 4More freedom of discretion for KIT 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3
... This product is designed to deparaffinize and ... formalin fixed paraffin-embedded tissue sections mounted on ... melting the paraffin at the high temperature ... with emulsification of the paraffin by detergent. ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
NEWBORN CALF SERUM AND PLASMA...
...
Biology Products: